Xeris - M&A Summary and Business Overview

Life ScienceCompany

Xeris M&A Summary

Xeris has acquired 1 company, including 1 in the last 5 years.

Xeris’ largest acquisition to date was in 2021, when it acquired Strongbridge Biopharma for $267M. Xeris has acquired in 1 US state. The Company’s most targeted sectors include life science (100%).

Xeris Business Overview

Where is Xeris headquartered?

Xeris is headquartered in Chicago, Illinois.

What is Xeris’ revenue?

Xeris disclosed revenue of 164M USD for 2023 and 110M USD for 2022.

How many employees does Xeris have?

Xeris has 377 employees.

What sector is Xeris in?

Xeris is a life science company.

When was Xeris founded?

Xeris was founded in 2005.

M&A Summary

  • M&A Total Activity1
    • M&A Buy Activity1
  • Total Sectors Invested 1
  • Total Countries Invested 1

Xeris

Xeris Pharmaceuticals, Inc.

180 North LaSalle Street, Suite 1600,
Chicago, Illinois 60601
United States,
(844) 445-5704
www.xerispharma.com

Xeris is a pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world. With a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke in the U.S. Its proprietary XeriSol and XeriJect formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. With Xeris’ technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system. Xeris was founded in 2005 and is based in Chicago, Illinois.


M&A Summary

Buy vs Sell

Year ≤ '19 '20 '21 '22 '23 '24 T
Buy (0.2/yr) # - - 1 - - - 1
vol $267M $267M
Sell (0.0/yr) # - - - - - - 0
  1

Most Recent M&A

Company Date Value Type
Strongbridge Biopharma plc 2021-05-24 267M USD Add-on Acquisition
Trevose, Pennsylvania · www.strongbridgebio.com
View All >>

M&A by Sector

Sector Buy # Value Sell # Value
Life Science 1 (100%) 267M (100%) - -
Total 1 $267M - -

By Geo

State/Country Buy Value Sell Value
United States 1 267M - -
  Pennsylvania 1 267M - -
Total 1 $267M - -

Deal Values

buy # Total
$100M to $1B 1 $267M
TOTAL $267M
Largest Strongbridge Biopharma plc
$267M (2021-05-24)

 Subscribe to unlock this and 207,390
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 200K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.